| Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028 |
47 |
| Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer |
36 |
| Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial |
33 |
| Validation of the 2018 FIGO cervical cancer staging system |
33 |
| Endometrial cancer: Molecular markers and management of advanced stage disease |
30 |
| The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes |
29 |
| SPERANZA project: HPV vaccination after treatment for CIN2+ |
27 |
| Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management |
26 |
| Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer |
26 |
| Uterine leiomyosarcoma: A review of the literature and update on management options |
26 |
| METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition |
25 |
| Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution |
23 |
| Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions |
22 |
| Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers |
21 |
| Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomes |
21 |
| Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028) |
21 |
| The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer |
20 |
| Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients |
20 |
| The fallopian tube, precursor escape and narrowing the knowledge gap to the origins of high-grade serous carcinoma |
19 |
| Impact of laparoscopic radical hysterectomy on survival outcome in patients with FIGO stage IB cervical cancer: A matching study of two institutional hospitals in Korea |
19 |
| Patient inflammatory status and CD4+/CD8+intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous |
18 |
| Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications |
18 |
| Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation |
18 |
| Who are the long-term survivors of high grade serous ovarian cancer? |
17 |
| Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition |
17 |
| Trends and comparative effectiveness of inpatient radical hysterectomy for cervical cancer in the United States (2012-2015) |
16 |
| TCGA molecular groups of endometrial cancer: Pooled data about prognosis |
16 |
| Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib |
16 |
| A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma |
15 |
| A phase II study of apatinib in patients with recurrent epithelial ovarian cancer |
15 |
| Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies |
15 |
| Molecular profiling and molecular classification of endometrioid ovarian carcinomas |
15 |
| Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis |
15 |
| Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study |
15 |
| A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer |
15 |
| Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors |
15 |
| Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-beta signaling pathway |
14 |
| Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review |
14 |
| Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy |
14 |
| Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5 |
14 |
| Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma |
14 |
| Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis |
14 |
| The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer |
13 |
| Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations |
13 |
| Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR alpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer |
13 |
| Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets |
13 |
| Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study |
13 |
| PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors |
13 |
| Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer |
13 |
| Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study |
12 |
